Gilead Announces Senior Management Promotion

Gilead Announces Senior Management Promotion

Posted on:04 Aug 09. FOSTER CITY, Calif.(BUSINESS WIRE)Aug. 3, 2009 Gilead Sciences, Inc. (Nasdaq:GILD) today announced the promotion of Gregg H. Alton to Executive Vice President, Corporate and Medical Affairs. He was previously Senior Vice President and General Counsel, responsible for legal, government and public affairs and international access operations, and recently assumed the additional responsibility of management for Gilead's global medical affairs activities and personnel. Mr. Alton will continue to report to John C. Martin, PhD, Gilead's Chairman and Chief Executive Officer.

"Gregg has established and built a number of critical functions at Gilead, and in doing so has demonstrated his leadership and his understanding of how every part of our organization contributes to delivering therapies to patients," said Dr. Martin. "Gregg's knowledge of public health and health policy will be instrumental to our medical affairs efforts across therapeutic categories. His promotion is recognition of Gregg's many contributions to our company and the importance of his continued leadership and vision."

Mr. Alton joined Gilead Sciences in 1999. From 2000 to 2009 he served as General Counsel. Prior to joining Gilead, Mr. Alton was an attorney at the law firm of Cooley Godward, LLP, where he specialized in mergers and acquisitions, corporate partnerships and corporate finance transactions for healthcare and information technology companies. Mr. Alton received a bachelor's degree in legal studies from the University of California at Berkeley, and holds a JD from Stanford University

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Pfizer's eczema hopeful has been building its case to challenge Sanofi and Regeneron's Dupixent, but safety issues could stand in its way.

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.